{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:23:31Z","timestamp":1779891811340,"version":"3.53.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s40263-019-00677-5","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T10:02:57Z","timestamp":1572861777000},"page":"1223-1228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1007","volume":"33","author":[{"given":"Amichai","family":"Perlman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maor","family":"Wanounou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotan","family":"Choshen Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mordechai","family":"Muszkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"key":"677_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.116.003725","author":"X Yao","year":"2016","unstructured":"Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016. \nhttps:\/\/doi.org\/10.1161\/jaha.116.003725\n\n.","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"677_CR2","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351. \nhttps:\/\/doi.org\/10.1056\/NEJMoa0905561\n\n.","journal-title":"N Engl J Med"},{"issue":"11","key":"677_CR3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1107039\n\n.","journal-title":"N Engl J Med"},{"issue":"10","key":"677_CR4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1009638\n\n.","journal-title":"N Engl J Med"},{"issue":"3","key":"677_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s00415-014-7462-0","volume":"262","author":"D Caldeira","year":"2015","unstructured":"Caldeira D, Barra M, Pinto FJ, Ferreira JJ, Costa J. Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol. 2015;262(3):516\u201322. \nhttps:\/\/doi.org\/10.1007\/s00415-014-7462-0\n\n.","journal-title":"J Neurol"},{"key":"677_CR6","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330\u201393. \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehy136\n\n.","journal-title":"Eur Heart J"},{"issue":"2","key":"677_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40256-015-0157-9","volume":"16","author":"B Vakkalagadda","year":"2016","unstructured":"Vakkalagadda B, Frost C, Byon W, et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. Am J Cardiovasc Drugs. 2016;16(2):119\u201327. \nhttps:\/\/doi.org\/10.1007\/s40256-015-0157-9\n\n.","journal-title":"Am J Cardiovasc Drugs."},{"issue":"1","key":"677_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1477-9560-11-10","volume":"11","author":"W Mueck","year":"2013","unstructured":"Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J. 2013;11(1):10. \nhttps:\/\/doi.org\/10.1186\/1477-9560-11-10\n\n.","journal-title":"Thromb J."},{"key":"677_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40261-015-0298-2","volume":"35","author":"J Mendell","year":"2015","unstructured":"Mendell J, Chen S, He L, Desai M, Parasramupria DA. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. Clin Drug Investig. 2015;35:447\u201353. \nhttps:\/\/doi.org\/10.1007\/s40261-015-0298-2\n\n.","journal-title":"Clin Drug Investig."},{"issue":"3","key":"677_CR10","doi-asserted-by":"publisher","first-page":"788","DOI":"10.4081\/cp.2015.788","volume":"5","author":"W Serra","year":"2015","unstructured":"Serra W, Li Calzi M, Coruzzi P. Left atrial appendage thrombosis during therapy with rivaroxaban in elective cardioversion for permanent atrial fibrillation. Clin Pract. 2015;5(3):788. \nhttps:\/\/doi.org\/10.4081\/cp.2015.788\n\n.","journal-title":"Clin Pract."},{"issue":"2","key":"677_CR11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.pjnns.2017.01.010","volume":"51","author":"C St\u00f6llberger","year":"2017","unstructured":"St\u00f6llberger C, Finsterer J. Recurrent venous thrombosis under rivaroxaban and carbamazepine for symptomatic epilepsy. Neurol Neurochir Pol. 2017;51(2):194\u20136. \nhttps:\/\/doi.org\/10.1016\/j.pjnns.2017.01.010\n\n.","journal-title":"Neurol Neurochir Pol"},{"issue":"52","key":"677_CR12","first-page":"A6568","volume":"157","author":"AJ Risselada","year":"2013","unstructured":"Risselada AJ, Visser MJ, van Roon EN. Pulmonary embolism due to interaction between rivaroxaban and carbamazepine. Ned Tijdschr Geneeskd. 2013;157(52):A6568.","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"1","key":"677_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.7861\/clinmedicine.18-1-103","volume":"18","author":"T Burden","year":"2018","unstructured":"Burden T, Thompson C, Bonanos E, Medford AR. Lesson of the month 2: pulmonary embolism in a patient on rivaroxaban and concurrent carbamazepine. Clin Med. 2018;18(1):103\u20135. \nhttps:\/\/doi.org\/10.7861\/clinmedicine.18-1-103\n\n.","journal-title":"Clin Med"},{"issue":"6","key":"677_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/1060028018759938","volume":"52","author":"PK King","year":"2018","unstructured":"King PK, Stump TA, Walkama AM, Ash BM, Bowling SM. Management of phenobarbital and apixaban interaction in recurrent cardioembolic stroke. Ann Pharmacother. 2018;52(6):605\u20136. \nhttps:\/\/doi.org\/10.1177\/1060028018759938\n\n.","journal-title":"Ann Pharmacother"},{"key":"677_CR15","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s11239-019-01866-1","volume":"48","author":"L Di Gennaro","year":"2019","unstructured":"Di Gennaro L, Lancellotti S, De Cristofaro R, De Candia E. Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant Therapy. J Thromb Thrombolysis. 2019;48:528. \nhttps:\/\/doi.org\/10.1007\/s11239-019-01866-1\n\n.","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"677_CR16","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s11239-018-01804-7","volume":"47","author":"A Perlman","year":"2019","unstructured":"Perlman A, Hochberg-Klein S, Cohen LC, et al. Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers. J Thromb Thrombolysis. 2019;47(4):590\u20135. \nhttps:\/\/doi.org\/10.1007\/s11239-018-01804-7\n\n.","journal-title":"J Thromb Thrombolysis"},{"key":"677_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09936-x","author":"RC Calizo","year":"2019","unstructured":"Calizo RC, Bhattacharya S, Hasselt JGCV, Wei C, Wong JS, Wiener RJ, et al. Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity. Nat Commun. 2019. \nhttps:\/\/doi.org\/10.1038\/s41467-019-09936-x\n\n.","journal-title":"Nat Commun"},{"key":"677_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003377","author":"NP Tatonetti","year":"2012","unstructured":"Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012. \nhttps:\/\/doi.org\/10.1126\/scitranslmed.3003377\n\n.","journal-title":"Sci Transl Med."},{"key":"677_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483\u20136. \nhttps:\/\/doi.org\/10.1002\/pds.677\n\n.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"677_CR20","unstructured":"Center for Drug Evaluation and Research. National Drug Code Directory. U.S. Food and Drug Administration. 2019. \nhttps:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/national-drug-code-directory\n\n. Accessed 13 June 2019."},{"key":"677_CR21","unstructured":"Cytochrome P-450 CYP3A4 inducers. DrugBank. 2019. \nhttps:\/\/www.drugbank.ca\/categories\/DBCAT003896\n\n. Accessed 13 June 2019."},{"issue":"11","key":"677_CR22","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1177\/1060028013504741","volume":"47","author":"T Hellwig","year":"2013","unstructured":"Hellwig T, Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants. Ann Pharmacother. 2013;47(11):1478\u201387. \nhttps:\/\/doi.org\/10.1177\/1060028013504741\n\n.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"677_CR23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s11239-019-01823-y","volume":"47","author":"JB Washam","year":"2019","unstructured":"Washam JB, Hohnloser SH, Lopes RD, et al. Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. J Thromb Thrombolysis. 2019;47(3):345\u201352. \nhttps:\/\/doi.org\/10.1007\/s11239-019-01823-y\n\n.","journal-title":"J Thromb Thrombolysis"},{"key":"677_CR24","unstructured":"Medication Guides. accessdata.fda.gov. 2019. \nhttps:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=medguide.page\n\n. Accessed 13 June 2019."},{"key":"677_CR25","unstructured":"Medicines. European Medicines Agency. 2019. \nhttps:\/\/www.ema.europa.eu\/en\/medicines\n\n. Accessed 13 June 2019."},{"issue":"4","key":"677_CR26","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1161\/STROKEAHA.118.023877","volume":"50","author":"K Macha","year":"2019","unstructured":"Macha K, Marsch A, Siedler G, Breuer L, Strasser EF, Engelhorn T, Schwab S, Kallm\u00fcnzer B. Cerebral ischemia in patients on direct oral anticoagulants. Stroke. 2019;50(4):873\u20139. \nhttps:\/\/doi.org\/10.1161\/STROKEAHA.118.023877\n\n.","journal-title":"Stroke"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00677-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-019-00677-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00677-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:42:50Z","timestamp":1604364170000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-019-00677-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,4]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["677"],"URL":"https:\/\/doi.org\/10.1007\/s40263-019-00677-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,4]]},"assertion":[{"value":"4 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A Perlman is a doctoral student at the Hebrew University of Jerusalem and an employee at K-health Inc. The work presented in this article is not related to his work at K-health. M. Wanounou, R. Goldstein, L. Choshen Cohen, D. Singer, and M. Muszkat declare that they have no potential conflicts of interest that might be relevant to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}